Rescheduling of Marijuana
The Justice Department is reclassifying FDA-approved and state-licensed marijuana as a less dangerous drug. Acting Attorney General Todd Blanche announced the change on Thursday. The announcement does not legalize marijuana across the United States.
The Justice Department is moving certain marijuana products from Schedule I to Schedule III. Schedule III is for substances with "a moderate to low potential for physical and psychological dependence". Blanche said on X that the Justice Department was "immediately rescheduling FDA-approved marijuana and state-licensed marijuana from Schedule I to Schedule III".
Impact on Research and Medical Use
Blanche stated that the rescheduling action allows for research on the safety and efficacy of this substance. He added that this will ultimately provide patients with better care and doctors with more reliable information. The department is also initiating an expedited hearing to consider the broader rescheduling of marijuana.
The decision to reclassify marijuana represents one of the most significant federal changes to marijuana policy in decades. It removes barriers to researching the drug's potential use. Advocates of looser restrictions have long argued that placing marijuana in the same category of highly addictive drugs as heroin has led to disproportionate rates of arrest and incarceration.
History of Marijuana Policy
The move follows a December executive order from President Donald Trump directing the Justice Department to loosen marijuana restrictions. His Democratic predecessor Joe Biden had taken similar steps to reclassify marijuana, but the process had not been finalised by the time he left office in January 2025.
Public Opinion and Market Growth
Marijuana is currently legal in some form in 40 US states. The US Centers for Disease Control and Prevention (CDC) has found that one in five people in the US reported using marijuana in the last year. A 2024 poll by the Pew Research Center found that 57 percent of US adults said that marijuana should be legal for both recreational and medical purposes.
Companies offering cannabis products have also become a lucrative industry. The market researcher BDSA is predicting $47bn in legal sales in 2026.
Future Hearings
Blanche has previously said that the US government would fast-track the process for a broader reclassification of marijuana. Hearings are set to begin in June.